UCB SA (OTCMKTS:UCBJF) Short Interest Down 26.9% in October

UCB SA (OTCMKTS:UCBJF) was the target of a large decline in short interest in October. As of October 15th, there was short interest totaling 211,100 shares, a decline of 26.9% from the September 30th total of 288,800 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 1,700 shares, the days-to-cover ratio is currently 124.2 days. Based on an average daily volume of 1,700 shares, the days-to-cover ratio is currently 124.2 days. Approximately 0.1% of the company’s stock are short sold.

UCB Stock Performance

OTCMKTS UCBJF opened at $265.96 on Monday. UCB has a 1 year low of $150.70 and a 1 year high of $306.79. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average price of $266.75 and a 200-day moving average price of $217.41.

Wall Street Analyst Weigh In

A number of brokerages have commented on UCBJF. Morgan Stanley restated an “overweight” rating on shares of UCB in a research note on Monday, September 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UCB in a research note on Monday, October 6th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.